Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
References: FDA Mounjaro Approval, FDA Zepbound Approval Indications and Contraindications Approved Uses Type 2 diabetes mellitus (as an adjunct to diet and exercise) Chronic weight management in adults with BMI 30 kg/m, or 27 kg/m with at least one weight-related comorbidity Contraindications Personal or family history of medullary thyroid carcinoma (MTC) Multiple endocrine neoplasia syndrome type 2 (MEN 2) Hypersensitivity to tirzepatide or any component of the formulation Note: Tirzepatide is not indicated for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis
Research involving this compound typically focuses on growth hormone secretagogue and GHRH pathway research, with attention to receptor activity, cellular signaling, and measurable pathway response in experimental models
Whilst these medications commonly cause gastrointestinal side effects including nausea, constipation, and diarrhoea, patients sometimes notice changes in bowel movement colour during treatment
CAS Number: 2023788-19-2
